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The structure of chromatin, which influences numerous
DNA-associated phenomena, such as transcription, re-
plication, recombination and repair, is controlled by a
complex combination of histone modifications, ATP-
dependent chromatin-remodeling enzymes, and nucle-
osome-assembly factors. The modification of histones
occurs at their N-terminal tails, which can be modified
by acetylation, phosphorylation, methylation, ubiq-
uitination, sumoylation, and ADP-ribosylation [1,2].
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Transcription factor Jun dimerization protein 2 (JDP2) binds directly to histones and DNA, and
inhibits p300-mediated acetylation of core histones and reconstituted nucleosomes that contain
JDP2-recognition DNA sequences. The region of JDP2 that encompasses its histone-binding domain
and DNA-binding region is essential to inhibit histone acetylation by histone acetyltransferases.
Moreover, assays of nucleosome assembly in vitro demonstrate that JDP2 also has histone-chaperone
activity. The mutation of the region responsible for inhibition of histone acetyltransferase activity
within JDP2 eliminates repression of transcription from the c-jun promoter by JDP2, as well as
JDP2-mediated inhibition of retinoic-acid-induced differentiation. Thus JDP2 plays a key role as
a repressor of cell differentiation by regulating the expression of genes with an activator protein 1
(AP-1) site via inhibition of histone acetylation and/or assembly and disassembly of nucleosomes.
Senescent cells show a series of alterations, including flatten and enlarged morphology, increase in
nonspecific acidic β-galactosidase activity, chromatin condensation, and changes in gene expres-
sion patterns. The onset and maintenance of senescence are regulated by two tumor suppressors,
p53 and retinoblastoma proteins. The expression of p53 and retinoblastoma proteins is regulated
by two distinct proteins, p16Ink4a and Arf, respectively, which are encoded by cdkn2a. JDP2 inhibits
recruitment of the polycomb repressive complexes 1 and 2 (PRC-1 and PRC-2) to the promoter of the
gene that encodes p16Ink4a and inhibits the methylation of lysine 27 of histone H3 (H3K27). The PRCs
associate with the p16Ink4a/Arf locus in young proliferating cells and dissociate from it in senescent
cells. Therefore, it seems that chromatin-remodeling factors that regulate association and dissoci-
ation of PRCs, and are controlled by JDP2, might play an important role in the senescence program.
The molecular mechanisms that underlie the action of JDP2 in cellular aging and replicative
senescence by mediating the dissociation of PRCs from the p16Ink4a/Arf locus are discussed.
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Among these modifications, the acetylation of histones
occurs at highest frequency and has been studied most
extensively, with the resultant identification of a num-
ber of histone acetyltransferases (HATs) and histone
deacetylases (HDACs), together with their target lysine
residues within specific histones in the chromatin. The
activities of HATs are not only antagonized by HDACs
but are also regulated by cellular and viral regulatory
factors that include histone chaperones and enzymes
that catalyze posttranslational modification [3,4].
Chromatin consists of structural units known as
nucleosomes. Each nucleosome consists of two histone
H2A–H2B dimers, a histone (H3–H4)2 tetramer, and
DNA that is wrapped around the resultant histone
octamers. During chromatin assembly, a histone
(H3–H4)2 tetramer is formed before the two hetero-
dimers H2Aand H2B are incorporated to form a nucleo-
some [5,6]. Regulation of transcription is associated with
alterations in chromatin structure that include histone
modifications and changes in nucleosome structure
[7–10]. Compaction of the chromatin and organization
of nucleosomes represent a barrier that has to be over-
come prior to activation of transcription. The N-terminal
histone tails that protrude from the nucleosomes do not
play a significant role in nucleosome formation, but they
appear to act as docking sites for other proteins and pro-
tein complexes to regulate chromatin compaction [9].
The structure of chromatin changes to allow greater
accessibility by transcription factors when a gene is
to be activated [9]. It has been suggested that the
change to a more accessible state not only involves the
modification of histones and alterations in nucleoso-
mal arrays, but also results from changes in nucleo-
some integrity that are due to displacement of histones
[11]. Furthermore, it has been demonstrated that his-
tone chaperones play a critical role in these processes
[12–15]. Thus it is tempting to speculate that histone
chaperones might be important for the compaction 
of chromatin, and it is now important to determine
whether certain co-repressors of transcription might
influence the deposition and assembly of nucleosomes
via regulation of histone-chaperone activity.
Primary cultures of untransformed cells stop
growing after several weeks and undergo senescence,
a phenomenon that is related to so-called cellular
aging. Senescence protects normal cells from abnor-
mal growth signals and oncogenic transformation, and
impairs their reprogramming to pluripotent stem cells
[16] by interrupting the cell cycle. Senescence is induced
not only by cellular aging, but also by the forced 
activation of the mitogen-activated protein (MAP)
kinase pathway and by genotoxic stressors, such as
hydrogen peroxide and certain DNA-damaging com-
pounds. Senescence increases the activities of two well-
known tumor suppressors, retinoblastoma protein (Rb)
and p53 protein. The expression of Rb and p53 is regu-
lated by two distinct proteins, p16Ink4a and Arf, respec-
tively, which are encoded by the cdkn2a locus [17].
The expression of p16Ink4a increases dramatically with
increasing numbers of cell divisions in primary fibro-
blasts in culture, and in rodent and human models 
in vivo. In this review, we summarize the roles of
p16Ink4a and Arf in the cell cycle, and describe a novel
mechanism for the regulation of their expression.
P16INK4A AND THE RB PATHWAY
Genes that are essential for cell-cycle progression are
transcribed at the beginning of G1 phase by the E2F
family of transcription factors. E2F is controlled by the
Rb family of proteins, pRb, p107, and p130 [18,19].
Early in G1, unphosphorylated Rb proteins bind to
the E2F family of proteins and inactivate their func-
tion [20,21]. During G1, the Rb proteins are inacti-
vated by phosphorylation by cyclin dependent kinase
4/6 (Cdk4/6)–cyclin D complexes, thereby allowing
the transcription of E2F-dependent genes, including
cyclin E. Upregulated cyclin E forms a complex with
cdk2 that mediates the hyperphosphorylation of the
Rb proteins, which is an essential requirement for
G1/S transition. p16Ink4a is an allosteric inhibitor of
cdk4/6. Binding to p16Ink4a changes the conformations
of cdk4/6, which prevents its interaction with cyclin D
[22,23]. Therefore, p16Ink4a acts as an inhibitor of the cell
cycle at G1 by modulating the Rb pathway. p16Ink4a is
often lost in a variety of human malignancies, includ-
ing glioblastoma, melanoma, and pancreatic adenocar-
cinoma [24]. In contrast, the upregulation of p16Ink4a
induces cell-cycle arrest and senescence [23,24].
ARF AND THE P53 PATHWAY
p53 is known to mediate cell-cycle arrest in G1 and G2,
and apoptosis. A number of downstream targets of p53
are involved in these processes, including p21Cip/waf1
in G1 arrest [25], 14-3-3 sigma and growth arrest and
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DNA damage inducer gene 45 (GADD45) in G2 arrest
[26,27], and p21, Bax, PI-3 up-regulation modulator
of apoptosis (PUMA), Fas/Apo1, and Killer/DR5 in
apoptosis [28–32]. p53 is regulated at the levels of pro-
tein stability and activity, and to some extent at tran-
scription and translation [33,34]. In unstressed cells,
p53 protein levels are very low because its degrada-
tion is mediated by the E3 ubiquitin ligase activity of
murine double minute 2 (MDM2), which targets p53
for ubiquitin-dependent proteolysis [35]. MDM2 is a
transcriptional target of p53, therefore, p53 directly
activates expression of its own negative regulator,
which produces a potent negative feedback regulatory
loop [36]. There are several stress-responsive kinases,
which, by phosphorylating p53, inhibit p53 degrada-
tion by MDM2 and increase its transcriptional activ-
ity [37–39]. DNA damage rapidly activates the ataxia
telangiectasia mutated and ataxia telangiectasia related
proteins, which phosphorylate the checkpoint kinases
1 and 2 (Chk1 and Chk2), which in turn propagate the
signal to downstream effectors such as p53 [40,41].
Chk1 and Chk2 phosphorylate p53 at Ser 20, which
prevents the efficient recruitment of MDM2. Thus
p53 is stabilized and its expression level is increased
in response to stress signaling. Arf is predominantly
localized in the nucleoli and is stabilized by binding
to nucleophosmin. In response to stress signaling, Arf
is released from nucleophosmin and translocates to
the nucleoplasm, where it interacts with MDM2,
inhibits its E3 ubiquitin ligase activity, and blocks the
nucleocytoplasmic shuttling of the MDM2–p53 com-
plex. Therefore, the consequences of the activation of
Arf are stabilization and activation of p53 [42,43].
TRANSCRIPTIONAL REGULATION OF P16INK4A
The transcriptional regulation of the p16Ink4a gene is an
important event in cellular senescence. Expression of
p16Ink4a is increased during replicative senescence and
in the premature senescence induced by oncogenic
activation. Its expression is regulated by transcriptional
activators such as Ets1/2 and the basic helix-loop-helix
(b-HLH) protein E47, as well as by transcriptional
inhibitors including the Id-1 HLH protein [44–47]. The
p16Ink4a locus is also epigenetically repressed by the
polycomb repressive complexes 1 and 2 (PCR-1 and
PCR-2, respectively), which methylate lysine 27 of his-
tone H3 (H3K27) [48]. In transformed cells, in which
the cell cycle is not arrested by a senescence program,
the CpG islands in the p16Ink4a promoter and exon 1 are
methylated and the p16Ink4a gene is silenced [49,50].
Understanding the role of all the factors that regu-
late the expression of p16Ink4a is important in clarifying
the molecular mechanism of cellular aging. We describe
here some of these factors, including transcriptional
activators and inhibitors, and epigenetic regulators.
Transcriptional activators
Both Ets1 and Ets2 activate p16Ink4a expression through
activation of the Ras-MEK-MAP kinase pathway by
directly binding to the ETS consensus sites in its pro-
moter [47]. In human fibroblasts, the hyperactivation
of Ets2 by overexpression of the Ras oncogene induces
G1 arrest, premature senescence, and increased expres-
sion of p16Ink4a. Ets2 seems to be the main regulator
of p16Ink4a expression during oncogenic premature
senescence, whereas Ets1 plays a role in replicative
senescence [51,52]. The basic helix-loop-helix (b-HLH)
protein E47 binds to DNA and proteins through its
basic and HLH domains, respectively. The E47 homod-
imer binds specifically to the E box (CANNTG) in the
p16Ink4a promoter [46]. Overexpression of E47 inhibits
the proliferation of some tumor cell lines by inducing
expression of p16Ink4a. Inhibition of E47 by RNA inter-
ference significantly reduces expression of p16Ink4a
and delays the onset of senescence [44]. Similarly, the
heterodimerization of E47 with ectopically expressed
Tal1 inhibits expression of p16Ink4a [53].
Transcriptional inhibitors
The expression of inhibition of differentiation protein-1
(Id-1) correlates negatively with p16Ink4a expression
during the process of senescence [44,47]. The expres-
sion of p16Ink4a in mouse embryonic fibroblasts (MEFs)
is higher in those from Id-1-deficient mice than in
wild-type MEFs [38]. Overexpression of Id-1 delays
replicative senescence by inhibiting p16Ink4a in human
keratinocytes and endothelial cells [54,55]. Id-1 does
not have a basic DNA-binding domain, unlike the 
b-HLH protein E47. Instead, Id-1 inhibits transcrip-
tion of p16Ink4a by heterodimerization with Ets2 [47].
Id-1 also heterodimerizes with E47, and inhibits its
transcriptional activity [56].
Epigenetic regulators
The p16Ink4a locus is also regulated epigenetically. The
locus is transcriptionally silenced by the trimethylation
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of lysine 27 of histone H3 (H3K27) in young proli-
ferating primary cells. In contrast, the expression of
p16Ink4a increases in aged and senescent cells with the
loss of H3K27 trimethylation [57]. Methylation of
H3K27 and silencing of the p16Ink4a locus are medi-
ated by PRC1 and PRC2. PRC1 contains a number 
of subunits, including polycomb (CBX2, 4, 6, 7 or 8 in
humans), polyhomeotic (PH1 or PH2 in humans), 
B lymphocyte molony murine leukemia virus insertion
region 1 homology (Bmi1), Ring1B, and other sub-
units [58], whereas PRC2 is composed of enhancer of
Zeste 2 (Ezh2), suppressor of Zeste 12 protein homolog
(Suz12), and embryonic ectoderm development (Eed)
subunits [48,59]. In PRC2, Ezh2 is the catalytic subunit
that methylates H3K27 [48], whereas the other com-
ponents are indispensible for the function of the com-
plex. Suz12 is essential for complex formation and 
di- and trimethylation of H3K27 in vivo [60,61]. In con-
trast, Eed is required for global H3K27 methylation,
including its monomethylation [62]. PRC1, the CBX
subunit recognizes and binds to trimethylated H3K27
[63,64]. Ring1B has E3 ligase activity for the ubiquity-
lation of histone H2A, whereas Bmi1 acts as a cofactor
[65,66]. Ubiquitylation of H2A by PRC1 prevents
transcript elongation by RNA polymerase II [67].
PRC1 has been shown by electron microscopy to
contribute to chromatin compaction [68]. Therefore, 
a possible molecular mechanism of PRC-mediated
gene silencing might involve trimethylation of histone
H3K27 by Ezh2 and the other subunits of PRC2. Then,
this acts as a binding site for PRC1, which ubiquitylates
H2A and compacts the chromatin, and leads to inhi-
bition of transcript elongation by RNA polymerase II.
PRCs might also inhibit earlier steps in transcrip-
tion, because PRC1 interacts with components of the
basal transcription machinery, the TATA-box-binding
protein-associated factors [69,70]. This inhibition does
not appear to involve blocking the access of RNA poly-
merase to the promoter, because the PRCs and tran-
scription factors bind to the target genes at the same
time [68,70–73]. In summary, p16Ink4a transcription is
inhibited by PRC2, which methylates histone H3K27,
which in turn recruits PRC1. PRC1 represses p16Ink4a
expression in young proliferating cells. In aged and
stressed cells, H3K27 trimethylation markers of PRC1
are lost and PRC1 dissociates from the p16Ink4a locus,
which results in transcriptional activation of p16Ink4a
by Ets1 and/or Ets2, and the entry of the cells into
senescence.
An important aim is to understand how the H3K27
trimethylation signal is lost in senescent cells. The pos-
sible explanations are as follows: (1) the action of as-yet-
unidentified histone demethylases and/or inhibitors
of the methyl transferases involved in H3K27 trimethy-
lation; or (2) histone chaperones recruit histone vari-
ants to the chromatin to alter gene expression. A recent
study has shown that the H3K27-specific demethy-
lase, Junonji domain-containing protein 3 (JMJD3) is
induced by Ras–Raf signaling, as well as by environ-
mental stresses. JMJD3 is recruited to the p16Ink4a locus
and contributes to the transcriptional activation of
p16Ink4a [74,75]. We propose that senescence is regu-
lated by Jun dimerization protein 2 (JDP2) of p16Ink4a,
which has histone-binding and chaperone activities
[74,75]. JDP2 is a member of the activator protein 1
(AP1) family of transcription factors, and activates
the transcription of p16Ink4a, as described below [76].
REGULATION OF ARF
The contribution of Arf to senescence is still controver-
sial. In general, it seems that p16Ink4a plays a central
role in senescence and tumor suppression in human
cells, whereas Arf has a relatively more prominent role
in mouse cells. In human cells, mutations are specifi-
cally found in p16Ink4a, rather than in Arf. Mutations of
p16Ink4a are frequently observed in primary cancers,
and occur during the establishment of immortal cell
lines [24,77]. Signaling by the Ras oncogene and telom-
ere shortening also induce p53- and Arf-independent
growth arrest [78,79]. In contrast, in MEFs, expression
of Arf correlates with the onset of senescence, and cells
that lack Arf do not become senescent in culture [80,81].
Mouse strains with targeted deletions in p16Ink4a or
Arf are tumor prone, whereas animals that lack p16Ink4a
and Arf have a more severe phenotype [53,81–84].
Signaling from oncogenic Ras activates transcription of
the cyclin-D-binding Myb-like protein 1 gene (Dmp1)
via the MAP kinase pathway and AP1 transcription
factors, such as c-Jun and Jun-B. DMP1 binds to and
activates transcription of the Arf promoter [85]. This
pathway is important, because oncogenic Ras fails to
activate Arf in MEFs from Dmp1-null mice [86].
Curiously, factors that activate Arf expression can
have different phenotypic effects: Ras induces sen-
escence, whereas Myc induces apoptosis. The over-
expression of Myc in B lymphocytes augments cell
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proliferation, which is counteracted by the Arf–p53–
MDM2 pathway. Suppression of this pathway inhibits
Myc-induced apoptosis and facilitates formation of
B-cell lymphoma [87]. However, another study has
shown that induction of Arf requires high and con-
tinuous Myc activity, and that physiological levels of
Myc are insufficient to stimulate the Arf promoter [88].
E2F TRANSCRIPTION FACTORS ACTIVATE
THE ARF PROMOTER
E2F1 stimulates expression of Arf and activates the
Arf–p53–p21WAF1 axis, which blocks cell proliferation.
This block is removed by the loss of function of the
Arf–MDM2–p53 pathway, which results in E2F1-
induced S-phase entry [89].
E2F family members bind directly to the Arf pro-
moter, as shown by chromatin immunoprecipitation
assay [90–92]. Ectopic expression of E2F1, E2F2 and
E2F3 activates the Arf promoter in human cells [90)]
In contrast, an isoform of E2F3, E2F3b, represses the
Arf promoter in MEFs [91]. Among the AP1 family 
of transcription factors, the c-Jun- and Fos-related
antigen-1 (Fra1) heterodimer is an activator of Arf
transcription in human and mouse cells. The knock-
down of Fos-related antigen-1 in human cells or a
deficiency of c-Jun in MEFs results in reduced expres-
sion of Arf [93]. In contrast, JunD seems to be a repres-
sor of Arf, because MEFs that lack JunD express
elevated levels of Arf, and display p53-dependent
growth arrest and premature senescence [94]. Arf is
also repressed transcriptionally by early growth re-
sponse protein 1 (Egr1) and Zbtb7a (pokemon). Egr1-
null MEFs express increased levels of Arf, but escape
replicative senescence with reduced expression of p53,
p21Cip1/Waf1 and other p53 downstream proteins [95].
Zbtb7a-null MEFs become senescent prematurely
because of the upregulation of Arf expression, because
senescence can be overcome by mutation of Arf [96].
SENESCENCE AND AGING IN HUMANS
AND MICE
Cellular senescence appears to be related to organism
aging. Cellular senescence involves processes that
include telomere shortening, accumulation of DNA
damage, and activation of the p16Ink4a/Arf locus. The
contributions of these factors to senescence seem to
differ in humans and mice. Cultured mouse fibrob-
lasts undergo senescence even when they have long
telomeres and high telomerase activity. Senescence is
abrogated by the loss of the p16Ink4a/Arf locus [82]. In
human cell cultures, the ectopic expression of telom-
erase is sufficient to overcome senescence by main-
taining the length of the telomeres [97]. In mice, the
maintenance of telomere length is important because
telomerase deficiency shortens their lifespan and
leads to premature aging [98–100]. The age-dependent
accumulation of INK4A has been observed in human
kidneys and skin [101,102], as well as in the majority
of mouse tissues [100,103]. In oncogene-induced senes-
cence, there is in vivo evidence that Arf is the impor-
tant factor in the activation of p53 tumor suppression
[103,104]. However, another study has shown that
components of the DNA-damage signaling cascade,
including ataxia telangiectasia mutated (Atm) and Chk2
proteins, are crucial for activation of p53 in response
to oncogenic signals [105–107]. These differences
between humans and mice could be attributable to
species specificity and/or experimental conditions.
Cellular senescence appears to be related to organism
aging because the same processes appear to be in-
volved. Genetic variants of the p16Ink4a/Arf locus are
linked to age-associated disorders, such as general
frailty, heart failure, and type 2 diabetes [108–113].
Mutations in telomerase or proteins that affect telom-
erase activity are linked to premature human aging syn-
dromes, including congenital dyskeratosis and aplastic
anemia [114]. There are increases in DNA mutations,
DNAoxidation, and chromosome loss during organism
aging. It seems reasonable to assume that all three
factors, activation of the p16Ink4a/Arf locus, telomere
shortening, and accumulation of DNA damage, have
cooperative effects on aging in physiological situations.
Understanding the mechanisms of cellular senescence
is currently of wide interest and it is important that we
identify new components of this process, such as JDP2.
HISTONE CHAPERONES
Activation and repression of gene expression at the
chromatin level are subject to regulation by enzymes
that reorganize and rearrange the chromatin template
[10]. Both ATP-dependent chromatin-remodeling com-
plexes and histone chaperones mediate an increase in
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the accessibility of promoters to transcription factors,
and facilitate histone-exchange reactions within the
nucleosomes [115,116]. Histone-exchange reactions are
important because they allow histone variants to be
incorporated into nucleosomal arrays independently
of the synthesis of DNA. The deposition of histone
variants, such as H2A.Z, has a major impact on gene
expression because these variants are known to be
localized within specific transcriptional domains and
within the heterochromatin [117,118].
In yeast cells, transcription is accompanied by the
disruption of nucleosomal structures, which suggests
an inverse correlation between gene activation and
nucleosome assembly [119]. Although sliding mecha-
nisms have been proposed to explain this phenome-
non, experimental evidence suggests that nucleosome
displacement can occur via disassembly of the nucle-
osome that involves the removal of histones [7–10].
Analysis of the expression of an inducible gene for
interleukin-2 also suggests the removal of histones from
the promoter of this mammalian gene upon activation
of transcription [120]. Histone chaperones are key play-
ers in the removal of histones in this context [121].
For example, nucleosome disassembly is mediated
by anti-silencing function 1 (ASF1)/CCG-1-interacting
factor (CIA), which is a histone chaperone and is essen-
tial for activation of gene transcription [121]. During
gene repression, however, ASF1/CIA-independent
reassembly of nucleosomes is observed in the same
system [121]. Thus regulation of transcription includes
the disassembly of nucleosomes for gene activation,
and deposition of histone nucleosomes and assembly
of nucleosomes for establishment of the basal or re-
pressed state. Some histone chaperones function with
components of several chromatin-related complexes,
which include HATs [122], HDACs [123], and the
ATP-dependent chromatin-remodeling complex [124].
Thus, acting in concert with other chromatin-related
factors, histone chaperones play important roles in
nuclear events that involve chromatin templates.
The histone chaperone known as nucleosome-
assembly protein-1 (NAP-1) acts autonomously to
exchange H2A–H2B dimers and to incorporate his-
tone variants into intact nucleosomes [118,125]. In vitro,
NAP-1 has been shown to facilitate the binding of
transcription factors to sites of nucleosomes, and this
process requires the disassembly of nucleosomes [126].
NAP-1 also associates with the co-activator p300/CBP,
with the resultant enhancement of p300-mediated
activation of transcription [127]. NAP-1 is, to date,
the best characterized histone-chaperone protein. The
crystal structure of NAP-1 reveals that it includes a
long α helix, which is responsible for homodimeriza-
tion, and a four-stranded antiparallel β sheet, as do
other histone-chaperone proteins [128].
A protein that is involved in the sorting of proteins
to vacuoles, designated Vps75, has been identified as
a member of the NAP-1 family of histone-chaperone
proteins in yeast [129]. It has a preference for (H3–H4)2
tetramers and forms a complex with Rtt109 (a protein
that participates in the regulation of Ty1 transposition)
[130]. The complex is composed of acetylated-only
free histone H3 in vitro, with no detectable activity
towards nucleosomal H3 [131]. Thus we speculate
that acetylation of lysine 56 of H3 is, at least in part,
regulated by the inability of Rtt109–Vsp75 HAT com-
plexes to acetylate nucleosomal H3 during the G2/M
phase of the cell cycle [131]. During DNA replication,
Rtt109 acetylates lysine 56 of histone H3 to promote
genome stability [132,133] in the premeiotic and mei-
otic S phases, and its activity is detectable when DNA
is damaged [134,135]. Efficient acetylation by Rtt109
requires a histone-chaperone protein, either ASF1 or
Vsp75, but not chromatin-assembly factor-1 (CAF-1)
[130]. By contrast, chromatin-assembly factor-1 and
Rtt106p mediate the formation of heterochromatin by
contributing to the spreading of Sir protein during the
early stages of heterochromatin formation [136].
English et al [137] have determined the crystal struc-
ture of a histone chaperone (ASF1/CIA) that binds to
a histone H3–H4 heterodimer. ASF1/CIA physically
blocks formation of (H3–H4)2 tetramers and the C
terminus of H4 undergoes a dramatic conformational
change upon binding to ASF1. Within nucleosomes, the
C terminus of H4 (residues 93–102) makes contact
with H2A and is bound within the nucleosome [5].
During nucleosome disassembly, H2A–H2B dimers
are removed by other histone chaperones and ATP-
dependent remodeling complexes, which exposes the
C terminus of H4 in the tetrasome complex [5,137,138].
ASF1 recognizes and captures the C terminus of
H4 in the tetrasome, which is the site of complex
changes in the conformation of the H4 C terminus in
the ASF–(H3–H4)2 complex. ASF1 then dissociates the
H3–H4 dimer that is bound to ASF1. Other histone
chaperones and chromatin-remodeling complexes
might also be involved in the dissociation of the
(H3–H4)2 tetramer. The reverse relationship might be a
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feature of nucleosome assembly. The histone (H3–H4)2
tetramer-disrupting activity of ASF1/CIA and the cry-
stal structure of the ASF1/CIA–histone H3–H4 dimer
complex provide some insight into the mechanisms
of both the assembly and disassembly of nucleosomes.
Recently Muto et al [139] have reported a compar-
ison of the crystal structures of template-activating
factor (TAF)-1β and NAP-1. They have found that the
two proteins are folded similarly, with the exception of
the inserted helix. These backbone helices are shaped
differently, and the relative disposition of each back-
bone helix and the “earmuff” domains between the
two proteins differ significantly. The histone-chaperone
activity is associated with the lower surface of the
earmuff domains [139]. Akai et al have reported that
the molecular complex between CIA/ASF-1 and the
double bromodomain complex plays a key role in site-
specific histone eviction at the active promoter [140].
DOMAINS THAT INTERACT WITH
CHROMATIN
We have defined five groups of nucleosome-binding
domains: bromodomains, chromodomains, WD40
repeats, tudor domains, and PHD fingers. Bromo-
domains recognize and bind acetylated lysine residues
[141,142]. For example, general control nonrepressive
5 (Gcn5) contains a bromodomain that is important
for the binding, recognition and retention of SAGA
on acetylated promoter nucleosomes [143]. Chromod-
omains bind methylated lysine tails specifically. The
chromodomain of heterochromatin protein 1 binds
methylated lysine 9 of H3, whereas the chromod-
omain of Polycomb binds methylated lysine 27 of H3
[144–148]. The chromodomain of Eaf3, a protein sub-
unit shared by the HAT complex NuA4 and the HDAC
complex Rpd3S, is important for the recognition of and
binding to methylated lysine 36 of H3 [149–151]. Loss
of this binding leads to increased acetylation in tran-
scribed regions and the formation of spurious tran-
scripts that are initiated within open reading frames
[151]. Unlike acetylation, methylation can occur once,
twice or three times, generating mono-, di- and
trimethylated histones, and the protein domains that
bind to methylated histones associate differentially
with histones with varying levels of methylation. The
WD-domain-containing protein WDR5 binds dimethy-
lated lysine 4 of H3 preferentially in vitro, in addition to
associating with a complex that also has HAT activity
[152]. The crystal structure that demonstrates recogni-
tion by WDR5 of lysine 4 dimethylated H3 shows how
the WDR repeats distinguish between the di- and
trimethylated lysine 4 residues of H3 [153,154]. Both
so-called tudor domains and WD-domain-containing
proteins are present in various HAT complexes, includ-
ing SAGA. Recently, a plant homeodomain, the PHD
finger, which has been found in a number of proteins
in various HAT complexes, has been shown to bind
to trimethylated lysine 4 of H3 [155–157]. An emerging
theme for these various chromatin-binding domains
is that they are often associated with enzymes that
modify or alter chromatin, such as Eaf3 and WDR5
[157,158], in the case of Gcn5 HAT [149]. To under-
stand fully the functions of these domains, we need
to study their locations within relevant protein 
complexes.
INTERACTION OF TRANSCRIPTION FACTORS
WITH HISTONES AND NUCLEOSOMES
Transcription factor IIIA (TFIIIA) is a 40-kDa protein,
with nine zinc finger domains, that binds specifically
to the internal promoter of the gene for 5S RNA and to
the N-terminal tail domains of histones H3 and H4,
but not those of H2A and/or H2B, and directly mod-
ulates its ability to bind nucleosomal DNA [159,160].
A new class of HAT-regulatory proteins has been
identified. These proteins block HAT activity via bind-
ing to and masking of the histone themselves. This
class includes the subunits of the inhibitor of histone
acetyltransferase (INHAT) complex; TAF-1α, TAF-1β,
and pp32, as well as ataxin 3; silencing mediator or
retinoid receptor corepressor/nuclear hormone recep-
tor corepressor; and proline-, glutamate- and leucine-
rich protein 1 [161–167]. Thanatos-associated protein 7
is known to associate with TAF-1β and to repress
transcription by inhibition of histone acetylation
[168,169]. This is a novel co-repressor that activates
INHAT binds directly to nucleosomes and core his-
tones, and prevents acetylation by HATs, thus acting
as a bona fide INHAT [170]. PU.1, a member of the Ets
family of oncoproteins, inhibits CBP-mediated acety-
lation of GATA-binding protein-1 (GATA-1) and ery-
throid Krüppel-like factor 2 (EKLF2), as well as of
histones, and disrupts acetylation-dependent tran-
scriptional events [171]. Moreover, PU.1 recruits the
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retinoblastoma tumor-suppressor protein, a histone
methyltransferase Suv39H, and heterochromatin pro-
tein 1 [172]. Similarly, proliferating cell nuclear anti-
gen binds to p300 to inhibit its HAT activity in vitro
and to block HAT-dependent transcription in vivo
[173]. TAF-1β and pp32 have also been shown to
interact with estrogen receptor-α (ER-α), to inhibit the
ERα-mediated activation of transcription, and activa-
tion of ER-α acetylation by p300 [166,167]. Moreover,
TAF-1β also interacts with the Sp-1 transcription fac-
tor and with KLF5, negatively regulating binding to
DNA and activation of transcription by these factors
[174,175]. Transcription factor nuclear factor-κB p50
can accommodate distorted, bent DNA within the
nucleosome [176], whereas the DNA-binding domain
of c-Myb binds to the N-terminal tails of H3 and H3.3,
and binding of c-Myb facilitates acetylation of histone
tails [177]. Moreover, kinetochore-null protein 2, which
has a c-Myb-like DNA-binding domain is specifically
required for loading of centromere-specific variants
of histone H3 (centromere protein A) in nematodes
and mammalian cells [178]. The recruitment of re-
pressive macroH2A nucleosomes requires direct
interactions between ATF-2 bound to the nearby 
AP-1 site and macroH2A and it is regulated by DNA-
induced protein allostery [179]. Thus the above-
mentioned sequence-specific DNA-binding factors
might regulate transcription either via histone cores
or tails, as well as via the structure of nucleosomes, 
in conjunction with other proteins that bind to the 
chromatin.
JDP2 REGULATES AP-1-MEDIATED
ACTIVATION OF TRANSCRIPTION
JDP2 has been identified as a binding partner of c-Jun
in yeast two-hybrid screening experiments, based on
the recruitment of the SOS system [180]. JDP2 forms
heterodimers with c-Jun and represses AP-1-mediated
activation of transcription [180]. Similarly, JDP2 was
isolated by yeast two-hybrid screening with activa-
tion transcription factor-2 (ATF-2) as the “bait” [181].
JDP2 has also been shown to associate with the
CAAT/enhancer-binding protein-γ [182] and the
progesterone receptor [183]. JDP2 is constitutively
expressed in many cell lines and represses the tran-
scriptional activity of AP-1 [184]. Moreover, JDP2 is
rapidly phosphorylated at threonine residue 148 when
cells are exposed to UV irradiation, oxidative stress,
or inhibitor-induced depressed levels of translation
by JNK [185]. Although a novel JNK-docking domain
is necessary for the p38-mediated phosphorylation of
JDP2 at threonine residue 148, this domain is not suf-
ficient for this process [186]. JDP2 binds to both cAMP-
and TRE-response elements on DNA as a homodimer,
and as a heterodimer with ATF-2 and members of the
Jun family, respectively [180,181]. JDP2 inhibits UV-
induced apoptosis by suppressing the transcription of
the p53 gene [187]. Given the roles of AP-1 in cellular
transformation and the reported repression of Jun-
and ATF-2-mediated transcription by JDP2, we have
demonstrated that JDP2 inhibits the oncogenic trans-
formation of chicken embryonic fibroblasts [188]. JDP2
also modulates the expression of cyclin D1 and p21,
which have opposing effects on cell-cycle progression.
JDP2 interferes with the progression of the cell cycle
by reducing the levels of cyclin D1 and at the same
time, increases the expression of p21 [189,190]. The
forced expression of JDP2 promotes the myogenic
differentiation of C2C12 cells, which is accompanied
by the formation of C2 myotubes and the strong expres-
sion of major myogenic markers. Moreover, the ectopic
expression of JDP2 in rhabdomyosarcoma cells induces
incomplete myogenesis and the incomplete forma-
tion of myotubes. These cells become committed to
differentiation via the p38-MAPK pathway [190]. A
similar enhancement of cell differentiation has been
reported during induction of osteoclast formation by
the receptor activator of the nuclear factor κB ligand
(RANKL) [191]. Unlike other members of the AP-1
family, the levels of JDP2 remain constant in response
to a large variety of stimuli, such as UV, irradiation,
and retinoic acid (RA), which affect the levels of other
factors involved in cell-cycle control. The induction
of JDP2 expression has only been observed during
the differentiation of F9 cells to muscle cells and
osteoclasts. Therefore, JDP2 might provide a thresh-
old for exit from the cell cycle and a commitment to
differentiation. Further studies on regulation of the
cell cycle and differentiation of cells induced by JDP2
should be instructive. It is also interesting that JDP2
is one of the candidate oncoproteins that collaborate
in the oncogenesis associated with the loss of p27, as a
result of insertional mutations [192]. Recent studies of
tumor cells have demonstrated that JDP2 is a tumor
suppressor [193]. We have also found that JDP2 is a
repressor of activation of transcription via AP-1, and
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a negative regulator of RA-induced differentiation of
mouse embryonic F9 cells [194,195].
JDP2 INHIBITS HAT ACTIVITY
We have reported previously that JDP2 represses the
transactivation mediated by p300 [195]. Both p300
and ATF-2 have HAT activity [196,197]. It was recently
shown that p300 acetylates ATF-2 protein in vitro at
lysine residues 374 and 357 and that ATF-2 is essen-
tial for the acetylation of histones H4 and H2B in vivo
[198,199]. We found that acetylation by p300 is inhibited
in a dose-dependent manner by JDP2, when added
exogenously. We also found that JDP2 was not acety-
lated by p300 under our experimental conditions. The
inhibitory effect of JDP2 on histone acetylation is in-
duced by p300, CREB binding protein (CBP), p300/CBP
associated factor (PCAF), and Gcn5. Overexpression
of JDP2 apparently represses RA-induced acetylation
of lysine residues 8 and 16 of histones H4 and H3.
JDP2 HAS INTRINSIC NUCLEOSOME-
ASSEMBLY ACTIVITY IN VITRO
The TAF-Iβ protein, which is a component of the
INHAT complex identified by Seo et al [162,163], is a
histone chaperone that binds directly to core histones
and facilitates the assembly of nucleosomes in vitro.
JDP2 interacts directly with all the core histones tested
and inhibits the p300-mediated acetylation of those his-
tones. To our surprise, JDP2 also introduces super-
coils into circular DNA in the presence of core histones,
to levels similar to those observed for yeast CCG1-
interacting factor 1 protein (yCia1p) and CIA1. There-
fore, JDP2 appears to have significant histone chaperone
activity in vitro [195]. We have also shown that the
HAT-inhibitory activity of JDP2 is involved, to some
extent, in the repression of transcription by JDP2,
whereas the maximal capacity of JDP2 to suppress
the RA-mediated activation of the c-Jun promoter
(Figure 1) [195; Figure 1] and to suppress adipocyte
differentiation [200] requires recruitment of HDACs.
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Figure 1. Schematic representation of the signal pathways of retinoic acid-induced differentiation of mouse embryonic carcinoma F9
cells. At the undifferentiated stage of F9 cells, histone deacetylase 3, nuclear hormone receptor corepressor, silencing mediator or
retinoid receptor corepressor and Jun dimerization protein 2 are recruited to the differentiation response element in the promoter region
of the c-jun gene to induce heterochromatin. In response to retinoic acid, the signals of p38, BRG1-based SWI/SNF complex, Ini1/Snf5
complex and p300/PCAF complex are recruited to the differentiation response element of the c-jun promoter, and the c-jun gene is
finally activated.
JDP2 REGULATES REPLICATIVE SENESCENCE
We have analyzed the aging-dependent proliferation
of MEFs from Jdp2–/– transgenic mice in the pres-
ence of environmental (20%) or low (3%) oxygen. The
Jdp2–/– MEFs continued to divide, even after 6 weeks,
whereas the wild-type MEFs almost stopped prolifer-
ating and entered senescence under environmental
oxygen. Conversely, neither wild-type nor Jdp2–/–
MEFs succumbed to replicative senescence at lower
oxidative stress. These results demonstrate that MEFs
that lack Jdp2 can escape from the irreversible growth
arrest caused by environmental oxygen. The expres-
sion of p16Ink4a and Arf were repressed in aged Jdp2–/–
MEFs (40 days) compared with their levels in wild-
type MEFs. In 3% oxygen, at the equivalent time (40
days), wild-type MEFs expressed lower levels of
p16Ink4a and Arf compared with those in 20% oxygen,
whereas Jdp2–/– MEFs maintained low-level expres-
sion of p16Ink4a and Arf. These observations indicate
that the aging-associated expression of p16Ink4a and
Arf is dependent on oxygen stress and that JDP2 con-
trols the expression of both p16Ink4a and Arf. We found
no dramatic downregulation of the upstream repres-
sors of p16Ink4a/Arf, Bmi1 and Ezh2, in the absence of
JDP2, which suggests that JDP2 does not regulate
their expression. JDP2 expression in wild-type MEFs
increases in the presence of 20% oxygen, but not in
the presence of 3% oxygen, which suggests that its
expression depends on oxygenic stress, and that accu-
mulated JDP2 plays a role in the transcriptional acti-
vation of p16Ink4a/Arf. Studies based on chromatin
immunoprecipitation have demonstrated that methy-
lation of H3K27 at the p16Ink4a/Arf locus is higher in
Jdp2–/– than wild-type MEFs, and that the binding of
PRC1 and PRC2 to the p16Ink4a and Arf promoters is
more efficient in Jdp2–/– MEFs. These observations
suggest that, in the absence of JDP2, H3K27 is methy-
lated by PRC2 and the p16Ink4a/Arf locus is silenced by
PRC1, whereas the increased expression of JDP2 helps
to release PRC1 and PRC2 from the p16Ink4a/Arf locus,
thereby reducing H3K27 methylation. Our data dem-
onstrate that JDP2 is an important factor for regula-
tion of cellular senescence. The loss of JDP2 allows
MEFs to escape senescence and conversely, overex-
pression of JDP2 induces cell-cycle arrest. The absence
of JDP2 reduces the expression of both p16Ink4a and
Arf, which inhibit cell-cycle progression. We propose
a model that takes into account these results. The
accumulation of oxidative stress and/or other envi-
ronmental stimuli during aging upregulate JDP2
expression in primary untransformed cells. Increased
JDP2 helps to remove PRC1 and PRC2, which are
responsible for the methylation of histone H3, from
the p16Ink4a/Arf locus, which leads to increased
p16Ink4a and Arf expression and entry into senescence
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Figure 2. Model for the epigenetic regulation of the p16Ink4a/Arf locus by Jun dimerization protein 2 (JDP2). Young primary cells
exposed to oxidative stress accumulate JDP2. In the presence of JDP2, polycomb repressive complexes 1 and 2 dissociate from the
p16Ink4a/Arf locus, and histone H3 on the promoter is demethylated. Finally, p16Ink4a and Arf are expressed and the aged cells become
senescent.
[76; Figure 2]. There is some evidence that Jdp2 
acts as a tumor suppressor: Jdp2 inhibits the Ras-
dependent transformation of NIH3T3 cells [193] and
Jdp2 gene disruptions are often found in lymphomas
induced by insertional mutagenesis caused by the
Moloney murine leukemia virus in MYC/Runx2
transgenic mice [201]. Here, we suggest that Jdp2 not
only inhibits the transformation of cells, but also
plays a role in the induction of cell senescence as well
as cell cycle arrest [202]. These functions of JDP2
might be important for its role in inhibiting tumor
formation. Our findings also provide new insights
into the molecular mechanisms by which senescence
is induced in the context of the epigenetic regulation
of the p16Ink4a/Arf locus.
CONCLUDING REMARKS
Like differentiation and tumorigenesis, senescence is
associated with dynamic changes in gene expression,
which are regulated by chromatin remodeling. Here,
we have shown that the expression of p16Ink4a and
Arf is upregulated in response to accumulating envi-
ronmental stresses, oncogenic signaling, and DNA-
damaging signals, and that they in turn induce
irreversible cell-cycle arrest by activating the Rb and
p53 pathways, respectively. The expression of p16Ink4a
and Arf is epigenetically regulated by PRC1 and PRC2,
which associate with these loci, methylate histone H3
in young cells, and dissociate in aged and senescent
cells. Several factors that upregulate or downregu-
late the expression of the p16Ink4a/Arf locus have been
reported. It is now important to establish how these
different factors regulate senescence. Do they affect
only euchromatin or do they also regulate hetero-
chromatin? Do they modify the chromatin structure
by recruiting HDACs, HATs, histone methyltrans-
ferases, histone chaperones, and/or other molecules?
Addressing these precise functions in the context of
epigenesis should help us to understand how senes-
cence and, in a broader context, aging, are regulated.
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Figure 3. Proposed model of the epigenetic regulation of the expression of the genes for p16Ink4a and Arf by Jun dimerization protein 2
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